Empower Clinics Inc. (CBDT.CN)

 

• Empower Clinics Kai Medical Lab to Launch FDA Approved Saliva-Based COVID-19 Test December 15. Previously Announced ABC-PCR Test Launches with Film & Tv Testing Contract Increasing To 10,000 Units Commencing December 7.

  Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company's COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and collegesVANCOUVER, BC / ACCESSWIRE / December 2, 2020 / EMPOWER CLINICS INC.
• ACCESSWIRE•7 days ago

  Empower Clinics Signs North American Distribution Agreement with API Pharma USA For FDA EUA COVID-Rapid Antigen & Antibody Tests. Supported Three Months of Clinical Trials

  EMPOWER'S KAI Medical Laboratory Also Supporting API Pharma With Health Canada Submission of COVID Rapid Antigen Test and Signs National Distribution AgreementVANCOUVER, BC / ACCESSWIRE / November 30, 2020 / EMPOWER CLINICS INC.
• ACCESSWIRE•12 days ago

  Empower Reports Q3 2020 Results With 67% Revenue Increase for The Nine Months Ended September 30, 2020

  VANCOUVER, BC / ACCESSWIRE / November 25, 2020 / EMPOWER CLINICS INC.

House Positions for C:CBDT from 20201207 to 20201207

House	Bought	$Val	Ave	Sold	$Val	Ave	Net	$Net
2 RBC	7,147,716	1,423,760	0.199	4,202,732	888,952	0.212	2,944,984	-534,808
7 TD Sec	9,609,604	1,923,829	0.20	7,949,336	1,629,625	0.205	1,660,268	-294,204
79 CIBC	4,176,016	840,230	0.201	2,663,634	550,355	0.207	1,512,382	-289,875
9 BMO Nesbitt	4,952,858	1,067,927	0.216	3,451,248	666,678	0.193	1,501,610	-401,249
89 Raymond James	1,038,174	204,215	0.197	117,441	23,061	0.196	920,733	-181,154
85 Scotia	2,888,766	553,224	0.192	1,987,707	402,200	0.202	901,059	-151,024
124 Questrade	2,247,465	461,585	0.205	1,373,970	280,145	0.204	873,495	-181,440
88 Credential	1,534,872	349,926	0.228	896,819	206,471	0.23	638,053	-143,455
19 Desjardins	935,267	174,978	0.187	717,504	135,524	0.189	217,763	-39,454
25 Odlum	100,000	21,500	0.215	0			100,000	-21,500
39 Merrill Lynch	91,253	18,111	0.198	18,051	3,544	0.196	73,202	-14,567
212 Virtu	1,872	396	0.212	10,914	2,204	0.202	-9,042	1,808
68 Leede	0			50,000	10,000	0.20	-50,000	10,000
28 BBS	0			50,501	10,694	0.212	-50,501	10,694
80 National Bank	595,994	126,196	0.212	647,751	137,136	0.212	-51,757	10,940
76 Industrial Alliance	0			55,800	12,660	0.227	-55,800	12,660
36 Latimer	17,791	3,841	0.216	79,998	16,167	0.202	-62,207	12,326
33 Canaccord	2,113,000	403,625	0.191	2,197,300	430,659	0.196	-84,300	27,034
62 Haywood	13,050	2,871	0.22	165,000	37,960	0.23	-151,950	35,089
59 PI	75,000	15,750	0.21	470,591	91,872	0.195	-395,591	76,122
83 Mackie	130,000	28,010	0.215	2,000,000	335,227	0.168	-1,870,000	307,217
13 Instinet	1,147,000	240,125	0.209	3,057,000	633,446	0.207	-1,910,000	393,321
1 Anonymous	11,533,850	2,321,512	0.201	18,186,251	3,677,028	0.202	-6,652,401	1,355,516
TOTAL	50,349,548	10,181,611	0.202	50,349,548	10,181,608	0.202	0	-3

Appili doses first participant in phase 3 Avigan trial

2020-12-02 09:32 ET - News Release

Dr. Armand Balboni reports

FIRST PATIENT DOSED IN APPILI THERAPEUTICS' PHASE 3 CLINICAL TRIAL OF AVIGAN TABLETS (FAVIPIRAVIR) FOR THE TREATMENT OF COVID-19 IN THE UNITED STATES

Appili Therapeutics Inc.'s investigators have dosed the first participant in its phase 3 trial (referred to as the PRESECO clinical trial) evaluating oral Avigan tablets (favipiravir) for the treatment of COVID-19. Appili has engaged PRA Health Sciences as a clinical research organization to administer the trial at 47 outpatient sites. The randomized, double-blind, placebo-controlled study will enroll approximately 826 participants. This study is the second Appili-sponsored COVID-19 clinical trial that has initiated dosing this quarter. Appili expects to report early data from the PRESECO study in the first half of 2021. Appili is initially focusing the trial in the United States but may expand the program to other areas of the world affected by COVID-19.

"Dosing the first participants in our first phase 3 trial is a significant milestone as we work to stem the tide of this coronavirus," said Dr. Yoav Golan, chief medical officer, Appili Therapeutics. "Early intervention with patients before they develop severe COVID-19 and require hospitalization remains a significant unmet need in the COVID-19 treatment landscape. As is the case with influenza, we believe that even with effective vaccines, oral anti-virals will play a critical role in treating COVID-19 and preventing its progression. Avigan's pill format and shelf-life stability make it particularly well suited for this endeavour and we look forward to gathering the necessary data to determine Avigan's utility for these patients."

Appili's COVID-19 Clinical Program

Appili is sponsoring three randomized, double-blind, placebo-controlled clinical studies to determine the safety and effectiveness of Avigan tablets in outpatients in multiple COVID-19 indications:

• The phase 3 PRESECO (preventing severe COVID disease) study aims to determine the efficacy of Avigan as a treatment for COVID-19 in patients with a positive COVID-19 test and mild-to-moderate symptoms, with the goal of alleviating symptoms and preventing disease progression before the infection requires hospitalizations or other intensive interventions;
• The phase 3 PEPCO (postexposure prophylaxis for COVID-19) study is evaluating Avigan in preventing the development of COVID-19 when given to asymptomatic individuals who have had direct exposure (within 72 hours) to an infected person; and
• The phase 2 CONTROL study is evaluating the use of Avigan to control outbreaks of COVID-19 in Canadian long-term care facilities, where the burden of severe disease and death is unusually high.

"We are fully committed to obtaining robust clinical data that demonstrates how Avigan may best fit into the full spectrum of a global pandemic response by addressing significant unmet needs," said Dr. Armand Balboni, chief executive officer, Appili Therapeutics. "Providing early access to anti-viral therapy is the cornerstone of our clinical strategy. Working with regulatory agencies and our partners, we have chosen to pursue a multipronged clinical trial approach, with triggers for treatment that include either a positive COVID diagnosis or known recent exposure to a COVID-19 case. Our target patient population includes those in the outpatient setting most vulnerable to the devastating effects of advanced COVID-19 infections, including those over 50, with significant co-morbidities, and front-line workers."

About Avigan (favipiravir)

Avigan is a broad-spectrum anti-viral in oral tablet form developed by FUJIFILM Toyama Chemical Co. Ltd. (FFTC) and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. Following promising clinical studies, Russia and India recently approved favipiravir-based anti-viral medications for the emergency treatment of COVID-19. FFTC recently announced positive phase 3 data in the use of Avigan in hospitalized COVID-19 patients.

Unlike most other interventions that researchers are evaluating in COVID-19, Avigan has already been thoroughly studied in human trials and has a well-known safety profile, with over 3,000 subjects receiving at least one dose of the drug. Avigan's oral tablet form is shelf-stable and has an established commercial manufacturing process, which may provide advantages over other COVID-19 interventions, which often require temperature-controlled storage and/or injection or intravenous administration.

Appili has joined a consortium of companies, including Dr. Reddy's Labs, Global Response Aid and FFTC, for the worldwide development and distribution of Avigan tablets for the potential treatment and prevention of COVID-19 (excluding Japan, China and Russia). This consortium is designed to ensure that Avigan is thoroughly evaluated in rigorous clinical studies and, if it receives the proper regulatory approvals, has the infrastructure in place to support worldwide distribution.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the anti-viral Avigan (favipiravir) for the worldwide treatment and prevention of COVID-19. The company is also advancing a diverse range of anti-infectives, including a broad-spectrum anti-fungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.

01 Communique releases 2021-2025 business plan

 

01 Communique releases 2021-2025 business plan

2020-11-16 16:24 ET - News Release

Mr. Andrew Cheung reports

01 COMMUNIQUE ANNOUNCES STRATEGIC GROWTH PLAN

01 Communique Inc. has released some of the key initiatives in its fiscal 2021 to 2025 business plan. The plan is designed to achieve growth in revenues and earnings. As support for the company's plan, the company has already secured major new global enterprise partners to help achieve its objectives and expects to add more new partners throughout fiscal 2021 and beyond.

As previously announced, the company will host a live webcast on Nov. 17 at 11 a.m. ET to discuss details of the plan. Investors are invited to register in advance for the live webcast of the call and investor presentation on the company's website.

Andrew Cheung, president and chief executive officer of 01 Communique, commented: "Q-Day, the day quantum computers are expected to render current encryption methods meaningless, is coming. 01 Communique has developed what we believe to be the first-to-market enterprise-level cybersecurity software for the quantum computing era. Our patent-pending, proprietary, quantum-safe cybersecurity products IronCAP and IronCAP X are expected to drive revenue growth. IronCAP, which was uncrackable during a month-long hack-a-thon last year, is expected to enable us to generate significant revenue as we grow our global client base."

Under Mr. Cheung's leadership and an exceptionally talented research and development team led by Sergey Strakhov as chief technology officer and Prof. Bezzateev as crypto scientist, 01 Communique has developed a variety of software-as-a-service technologies over the past 20 years. In addition to IronCAP X, revenue-generating products include I'm InTouch remote access software and I'm OnCall remote support. Revenue from these two products has helped the company finance the development of IronCAP X.

Mr. Cheung stated: "Now we are launching our game-changing, enterprise-level IronCAP X quantum-safe cybersecurity product to the global market. Over the next few years, we expect to invest in our infrastructure to support the growth of our business."

Key investment highlights

The company is providing its key investment highlights, which have been outlined in a presentation that will be available shortly after tomorrow's webcast on the company's website.

The company is:

• Serving a massive global encryption software market forecasted to grow from $600-million (U.S.) in 2018 to $1.7-billion (U.S.) in 2024, representing a CAGR (compound annual growth rate) of 18.7 per cent (1);
• Targeting global postquantum cryptograph vertical markets, which include e-mail encryption, file storage, website protection and financial transactions;
• Planning to launch IronCAP X enterprise version in first quarter 2021 (2) with world-class early-adopter partners;
• One of the first to market with proprietary, patent-pending, enterprise software for the quantum computing era that the company believes has the potential to become the de facto solution globally;
• A disruptive cybersecurity SaaS company with an aggressive plan to generate increased revenue and net income margin growth;
• At a financial inflection point which provides an attractive investment entry point, Q-day represents a massive potential catalyst for investors.

Strategic growth plan

The plan is designed to achieve growth in revenues and earnings. Revenue growth is expected to be driven by being one of the first to market with quantum-safe encryption technology, which the company anticipates will enable it to rapidly add new enterprise customers. It will be supported by free IronCAP X licences to individuals, which are expected to accelerate adoption of the technology.

The company's goal is to become the de facto solution globally for quantum-safe encryption. The advent of quantum computers has implications for every electronic communication, file storage, website and financial transaction as Q-day is expected to render current encryption methods meaningless.

Over the next few years, the company expects to make significant investments in company infrastructure. This includes not only marketing, sales and business development, but also R&D, finance and business processes. The company expects these investments to support the growth of the business, thereby enabling significant future levels of profitability.

About 01 Communique Inc.

Established in 1992, 01 Communique has always been at the forefront of technology. The company's cybersecurity business unit focuses on postquantum cybersecurity with the development of its IronCAP technology. IronCAP's patent-pending cryptographic system is an advanced Goppa-code-based postquantum cryptographic technology that can be implemented on classical computer systems as known today and at the same time can also safeguard against attacks in the future postquantum world of computing. The company's remote access business unit provides its customers with a suite of secure remote access services and products under its I'm InTouch and I'm OnCall product offerings. The remote access offerings are protected in the United States by its patents No. 6,928,479/No. 6,938,076/No. 8,234,701; in Canada by its patents No. 2,309,398/No. 2,524,039 and in Japan by its patent No. 4,875,094.

(1) Gartner Forecast Analysis: Information Security and Risk Management, Worldwide, report -- July, 2020.

(2) IronCAP and IronCAP X, a new cybersecurity product for e-mail/file encryption, incorporating patent-pending technology, was made available for commercial use on April 23, 2020. The enterprise version is expected to be available in first quarter 2021.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.